Docetaxel/cisplatin.: A palliative therapy concept in advanced gastric cancer

被引：0
|
作者：
Ridwelski, K [1 ]
Gebauer, T [1 ]
Fahlke, J [1 ]
Kröning, H [1 ]
Kettner, E [1 ]
Lippert, H [1 ]
机构：
[1] Otto Von Guericke Univ, Hosp Surg, Magdeburg, Germany
来源：
3RD INTERNATIONAL GASTRIC CANCER CONGRESS | 1999年
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Between 1/97 to 10/98 43 patients (pts.)- 30 male and 13 female - with advanced or metastatic gastric cancer (median age of 62.4 (39-75) years) were enrolled in our study. The study finished 39 pts. according to protocol. After application from Docetaxel 75 mg/sqm and Cisplatin 75 mg/sqm we saw 4 CR (10,3%), 12 PR (30,8%), 1 MR (2,5%), 10 SD (25,5%) und 12 P (30,8%). The ORR was 17/39 (43.6%). The median survival time was 12.5 months and the median time to progression 5,8 months. These results show, that the combination of Docetaxel and Cisplatin is a high effective polychemotherapy regarding RR and median survival time. The protocoll could also be proofen as a neoadjuvant concept.
引用
收藏
页码：773 / 777
页数：5
相关论文
共 50 条
  • [21] Conversion therapy for initially unresectable advanced gastric cancer after combination chemothrapy of docetaxel, cisplatin and S-1
    Mieno, Hiroaki
    Katada, Natsuya
    Ushiku, Hideki
    Ema, Akira
    Moriya, Hiromitsu H. M.
    Hosoda, Kei
    Yamashita, Keishi
    Naitou, Masanori
    Kikuchi, Shiro
    Watanabe, Masahiko
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2014, 219 (04) : E170 - E170
  • [22] A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy
    Liang, Yao
    Maeda, Osamu
    Miyata, Kazushi
    Tanaka, Chie
    Kanda, Mitsuro
    Shimizu, Dai
    Fukaya, Masahide
    Koike, Masahiko
    Kodera, Yasuhiro
    Ando, Yuichi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (05) : 661 - 667
  • [23] A Multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer
    Fahlke, J.
    Ridwelski, K.
    Schmidt, C.
    Hribaschek, K.
    Stuebs, P.
    Kettner, E.
    Quietzsch, D.
    Assmann, M.
    Deist, T.
    Keilholz, U.
    Lippert, H.
    CHEMOTHERAPY, 2007, 53 (06) : 454 - 460
  • [24] Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer
    Luo, Haiqing
    Yu, Zhonghua
    Gao, Hongfei
    Guan, Chengnong
    Xu, Meng
    JOURNAL OF BUON, 2013, 18 (01): : 154 - 161
  • [25] Survival analysis of linitis plastica advanced gastric cancer patients receiving S-1 plus cisplatin.
    Kumekawa, Yosuke
    Chin, Keisho
    Osumi, Hiroki
    Ogura, Mariko
    Ozaka, Masato
    Suenaga, Mitsukuni
    Shinozaki, Eiji
    Matsusaka, Satoshi
    Sano, Takeshi
    Mizunuma, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Docetaxel and Cisplatin Plus Fluorouracil Compared With Modified Docetaxel, Cisplatin, and 5-Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Retrospective Analysis of Single Institution
    Inal, A.
    Kaplan, M. A.
    Kucukoner, M.
    Isikdogan, A.
    NEOPLASMA, 2012, 59 (02) : 233 - 236
  • [27] Clinical benefit of palliative radiation therapy in advanced gastric cancer
    Kim, Michelle M.
    Rana, Vishal
    Janjan, Nora A.
    Das, Prajnan
    Phan, Alexandria T.
    Delclos, Marc E.
    Mansfield, Paul F.
    Ajani, Jaffer A.
    Crane, Christopher H.
    Krishnan, Sunil
    ACTA ONCOLOGICA, 2008, 47 (03) : 421 - 427
  • [28] Docetaxel for advanced gastric cancer? Reply
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (17) : 2491 - 2493
  • [29] Docetaxel combination for advanced gastric cancer
    Senior, Kathryn
    LANCET ONCOLOGY, 2007, 8 (09): : 764 - 764
  • [30] Docetaxel in combination for advanced gastric cancer
    Jaffer A. Ajani
    Gastric Cancer, 2002, 5 (Suppl 1) : 31 - 34
12345